THIS WEEK
The FDA approved a new oral GLP-1 pill on April 1 with no food or water restrictions, a meaningful mechanistic departure from oral semaglutide that most coverage has glossed over. We break down the ATTAIN trial data and what the head-to-head comparison with oral semaglutide actually shows. On the compounding front, the FDA announced on April 15 that seven peptides including BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP will go before its advisory panel in July for review. This is not an approval. It is the beginning of a process that typically takes 6 to 12 months after committee review to reach a final FDA decision. The Regulatory Radar section this week covers exactly what that distinction means and what readers with active prescriptions should know right now.
The First Oral GLP-1 With No Food or Water Restrictions
Orforglipron (Foundayo) — FDA Approved April 1, 2026
On April 1, 2026, the FDA approved orforglipron under the brand name Foundayo for adults with obesity or overweight with at least one weight-related comorbidity. It is the first oral GLP-1 receptor agonist that can be taken at any time of day without food or water restrictions. That single sentence contains a mechanistic distinction worth understanding before you read the trial numbers.
The ATTAIN Phase 3 program enrolled more than 4,500 participants across two registration trials. ATTAIN-1 enrolled 3,127 adults without diabetes. At 72 weeks, weight loss was 7.5% at the lowest studied dose, 9.3% at the mid dose, and 11.2% at the highest dose, compared to 2.1% in the placebo group. ATTAIN-2 enrolled 1,613 adults with type 2 diabetes. Weight reductions ranged from 5.1% to 9.6% versus 2.5% in the placebo group, with significant improvements in HbA1c across all doses.
These numbers are meaningful but they are not the headline. Oral semaglutide, approved in December 2025 under the brand Wegovy oral, produces comparable weight loss in the 14% to 15% range at its maximum dose. The more important difference is pharmacological: orforglipron is a small molecule, not a peptide. That distinction is what drives the no-food-restriction advantage and it is covered in full in Mechanism Corner this week.
The safety profile includes the standard GLP-1 gastrointestinal effects: nausea, constipation, diarrhea, vomiting. Orforglipron carries a boxed warning for potential thyroid C-cell tumors, consistent with the class. The higher dose showed GI discontinuation rates of up to 9.7% in the ACHIEVE-3 head-to-head trial, compared to 4.9% with oral semaglutide 14 mg. That tradeoff is real and matters for the clinical decision.
The bottom line on orforglipron: it works, it is FDA approved, and the no-food-restriction advantage is pharmacologically genuine rather than a marketing claim. It is not more effective than injectable GLP-1s or tirzepatide. It occupies a real niche for patients who want an oral option without the absorption constraints of semaglutide tablets. The access pricing is notable: as low as $25 per month with commercial insurance savings card, $149 per month self-pay at the lowest dose, and $50 per month for eligible Medicare Part D patients beginning July 1, 2026.
Full premium section continues with the ACHIEVE-3 head-to-head trial data versus oral semaglutide, dose-by-dose weight loss breakdown, tolerability comparison, and how to think about this approval in the context of the broader oral GLP-1 market.
ACHIEVE-3: The Head-to-Head Against Oral Semaglutide
The ACHIEVE-3 trial is the only published head-to-head comparison of two oral GLP-1 receptor agonists. It compared orforglipron 36 mg against oral semaglutide 14 mg in adults with type 2 diabetes on metformin. Orforglipron 36 mg reduced HbA1c by 2.2% versus 1.4% for oral semaglutide 14 mg. Weight reduction was 19.7 pounds with orforglipron compared to 11.0 pounds with oral semaglutide. Additional improvements in lipids, systolic blood pressure, and triglycerides were seen in both arms, with orforglipron numerically superior across most cardiometabolic endpoints.
GI discontinuation rates were 9.7% with orforglipron versus 4.9% with oral semaglutide. Mean pulse increases were also higher with orforglipron. These are not trivial differences for a patient population where GI tolerability is already the primary reason for discontinuation across the GLP-1 class.
Dose-by-Dose Breakdown from ATTAIN-1 (no diabetes, n=3,127, 72 weeks)
6 mg: 7.5% weight loss vs 2.1% placebo. 12 mg: 9.3% weight loss vs 2.1% placebo. 36 mg: 11.2% weight loss vs 2.1% placebo. Improvements in waist circumference, blood pressure, and lipids were dose-dependent across all groups.
Dose-by-Dose Breakdown from ATTAIN-2 (type 2 diabetes, n=1,613, 72 weeks)
3 mg: 5.1% weight loss vs 2.5% placebo. 12 mg: 7.9% weight loss vs 2.5% placebo. 36 mg: 9.6% weight loss vs 2.5% placebo. HbA1c reductions were significant across all doses. More than 65% of participants taking the highest dose achieved an HbA1c at or below 6.5%.
Approved Tablet Strengths and Pricing
Orforglipron is available as oral tablets at six strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. Note that trial dose nomenclature differs from approved tablet strengths: confirm current prescribing information for the dose titration schedule before initiating. Eligible patients with commercial insurance may pay as little as $25 per month with a Lilly savings card. Self-pay pricing starts at $149 per month for the lowest dose. Medicare Part D patients may access the drug for $50 per month beginning July 1, 2026.
What This Approval Does Not Tell You
Orforglipron has not been compared head-to-head with injectable semaglutide or tirzepatide. Based on available data, it does not compete on raw weight loss numbers with the injectable class or with tirzepatide specifically. The SUMMIT cardiovascular outcomes trial is ongoing and no cardiovascular benefit has been demonstrated yet. The thyroid C-cell tumor boxed warning is class-wide and does not reflect a specific orforglipron safety signal beyond the class risk.
The Framework for Choosing Between Oral GLP-1 Options
Two oral GLP-1 receptor agonists are now available in the United States: oral semaglutide (Wegovy oral, approved December 2025) and orforglipron (Foundayo, approved April 1, 2026). The ACHIEVE-3 head-to-head trial provides the only direct comparative data and the results support a clear but nuanced framework for decision-making.
When Orforglipron Has the Advantage
If the primary goal is maximum metabolic efficacy from an oral agent, orforglipron at the higher doses is the stronger option based on ACHIEVE-3. The glycemic reduction advantage (2.2% vs 1.4% HbA1c) and weight loss advantage (19.7 lb vs 11.0 lb) are both clinically meaningful in a type 2 diabetes population on metformin. The no-food-restriction requirement is a genuine convenience advantage for patients with variable schedules or who struggle with the oral semaglutide fasting protocol. For patients already succeeding on oral semaglutide who want to switch for better glycemic control, the comparative data supports that orforglipron offers a meaningful step up in efficacy.
When Oral Semaglutide Has the Advantage
If GI tolerability is a primary concern or the patient has a history of GI complications, oral semaglutide has a meaningfully lower GI discontinuation rate: 4.9% versus 9.7% at the doses tested in ACHIEVE-3. The pulse increase signal with orforglipron requires monitoring in patients with cardiac conditions or elevated baseline heart rate. For patients in whom the empty stomach requirement is not a practical burden, the tolerability profile of oral semaglutide may warrant its use as a first-line oral option.
What Neither Option Replaces
Both oral GLP-1 options produce less weight loss than injectable tirzepatide (Zepbound), which demonstrated 20.9% weight loss at 72 weeks in SURMOUNT-1, or injectable semaglutide at 2.4 mg (Wegovy), which demonstrated 14.9% at 68 weeks in STEP-1. The oral route involves a real efficacy tradeoff for patients who are candidates for injectable therapy and can tolerate it. The decision between oral and injectable should be driven by patient preference, tolerability, and clinical goals rather than by assumptions about route equivalence.
A Note on Titration
Both oral agents require slow dose titration to manage GI tolerability. Orforglipron titration in the ATTAIN program started at lower doses and escalated over multiple weeks. The approved tablet strengths (0.8 mg through 17.2 mg) suggest a six-step titration schedule. Rushing titration is the primary driver of GI discontinuation in the GLP-1 class. Any protocol decision should include an explicit titration plan with dose holds if GI effects exceed tolerability thresholds.
The Peptide Delivery Problem and Why It Has Not Been Solved
The no-food-restriction advantage of orforglipron follows directly from its chemistry. Understanding it clarifies a fundamental constraint on every peptide-based oral drug, including oral semaglutide, oral insulin, and the broader class of therapeutic peptides tracked in this publication.
Why Oral Peptides Are Hard
GLP-1 receptor agonists work by binding to the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, gut, brain, and cardiovascular system. The receptor does not care whether the binding molecule is a peptide or a small molecule. What matters is binding affinity, downstream signaling, and pharmacokinetics of delivery.
Oral semaglutide is a peptide: a chain of amino acids with a molecular weight of approximately 4,114 Da. Peptides face two significant challenges with oral delivery. First, proteolytic enzymes in the gastrointestinal tract degrade them rapidly. Peptide bonds are specifically targeted by gut proteases including pepsin, trypsin, and chymotrypsin. Second, the large molecular size and hydrophilicity of peptides mean poor passive absorption across intestinal epithelium.
The SNAC Solution and Its Constraint
Novo Nordisk addressed the oral delivery problem for semaglutide by co-formulating it with SNAC, an absorption enhancer that creates a local pH environment in the stomach that partially protects semaglutide from degradation and facilitates absorption at the gastric mucosa rather than the intestine. This is a genuinely clever formulation solution. The problem is that the mechanism is exquisitely sensitive to the presence of food and water: even a small amount of either dilutes the SNAC effect and dramatically reduces bioavailability. Hence the 30-minute empty stomach requirement with no more than 4 oz of plain water.
Why Orforglipron Does Not Have This Problem
Orforglipron has a molecular weight of approximately 530 Da. It is a small molecule, not a peptide. At this size, it crosses intestinal epithelium through passive transcellular diffusion, a mechanism that is not dependent on the SNAC trick and is not disrupted by the presence of food or water. There is nothing to protect from proteolysis because there are no peptide bonds to cleave. The absorption mechanism is fundamentally different and the food restriction requirement simply does not apply.
What This Means for the Broader Peptide Space
Orforglipron is not evidence that oral peptide delivery has been solved. It is evidence that small molecules targeting the same receptors as peptides can achieve similar outcomes without the delivery constraints. The oral delivery problem for peptides remains. Every peptide in this publication that is used via subcutaneous injection, from BPC-157 to SS-31 to ipamorelin, requires that route because the oral alternative is not pharmacologically viable with current formulation technology. SNAC is the best available workaround for one specific peptide. It is not a generalizable platform.
The implication for readers tracking the peptide space: do not read orforglipron as validation that oral versions of currently injectable peptides are on the near horizon. The chemistry does not work that way. The peptide delivery problem is real, it is unsolved, and orforglipron succeeded precisely because it is not a peptide.
What the FDA Actually Announced on April 15
On April 15, 2026, the FDA published a federal notice confirming that its Pharmacy Compounding Advisory Committee will meet on July 23 and July 24 to evaluate seven peptide compounds for possible inclusion on the 503A Bulks List, the list of substances that licensed compounding pharmacies can legally prepare for individual patients under a physician prescription.
The compounds under review are as follows. July 23: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis. July 24: Emideltide (also known as DSIP) for opioid withdrawal, chronic insomnia, and narcolepsy, Semax for cerebral ischemia, migraine, and trigeminal neuralgia, and Epitalon for insomnia.
Three Things This Announcement Is Not
It is not an FDA approval. Drug approval requires demonstrated safety and efficacy through Phase 1 through Phase 3 clinical trials and a full FDA review. None of these compounds have completed that process.
It is not a clearance for compounding. Placement on the 503A Bulks List means a licensed 503A compounding pharmacy can prepare the substance for an individual patient with a valid prescription. It does not mean the compound is approved, it does not mean the compound has been found safe and effective, and it does not mean any vendor can sell it without restriction.
It is not immediate. The committee meets in July. The committee makes non-binding recommendations. The FDA retains final authority and typically takes 6 to 12 months after a committee meeting to issue a final determination. For BPC-157 specifically, a positive committee recommendation in July would mean an FDA decision sometime in early to mid 2027 at the earliest.
What Actually Changed on April 15
HHS Secretary Kennedy directed the FDA to move these compounds from the Category 2 restricted list to PCAC review. That is a procedural step, not a regulatory clearance. Category 2 classification meant the FDA had determined there was insufficient evidence of safety for compounding. Moving to PCAC review means the question is being formally revisited, not that the answer has changed.
What This Means Right Now for Readers With Active Prescriptions
The compounds are still restricted. Compounding pharmacies that stopped producing BPC-157, TB-500, and the others following the 2023 restrictions cannot legally resume production based on this announcement. The legal status does not change until the FDA issues a final determination after the PCAC review process is complete.
One Detail Worth Watching
The PCAC currently has several vacancies. HHS Secretary Kennedy has the authority to fill those vacancies with new appointments before July, and those appointments could influence the committee composition and its recommendations. This is a detail that regulatory oversight advocates have flagged. The docket number for public comment is FDA-2025-N-6895. Comments submitted before July 9, 2026 will be provided to the committee. This is a legitimate avenue for researchers, practitioners, and patients to submit evidence on any of the seven compounds under review.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use